Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | EVP Research & Development | October 06, 2026 | October 06, 2026 |
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date October 06, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 153,902 |
Ending reported balance
After 2026-10-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 3,500 · Balance 157,402 Row 2 · 2026-10-06 · Sale · Disposed 3,500 · Balance 153,902 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2028-02-27 | Direct | 19,886 |
Reported balance
After 2026-10-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-06 · Exercise / conversion · Disposed 3,500 · Balance 19,886 |
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,862 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 22,862 · Balance 52,862 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2036-06-18 | Direct | 64,860 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Grant · Acquired 64,860 · Balance 64,860 F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
F2: This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $13.68 | $5,470.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 18 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,134 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 900 | $13.65 | $12,285.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 17 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,534 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 600 | $13.60 | $8,160.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 16 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,434 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 300 | $13.55 | $4,065.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 15 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,034 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $13.35 | $5,340.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 14 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,334 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $13.30 | $2,660.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 13 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,734 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $13.25 | $2,650.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 12 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,934 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 400 | $13.23 | $5,290.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 11 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,134 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 300 | $13.20 | $3,960.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 10 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,534 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 100 | $13.18 | $1,317.50 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 9 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,834 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,300 | $13.15 | $17,095.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 8 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,934 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,639 | $11.10 | $29,292.90 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 7 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,234 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29,2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 300 | $13.13 | $3,937.50 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 6 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,595 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 694 | $11.10 | $7,703.40 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 5 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29,2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 800 | $13.10 | $10,480.00 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,201 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 2,639 | $11.10 | $29,292.90 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29,2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 178 | $13.05 | $2,322.90 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,362 F2 · kind: The sale(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2017. Read SEC document |
| November 01, 2017 Filed Nov 4, 2017 00:27 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 694 | $11.10 | $7,703.40 |
DisclosureSEC source: 0001061983-17-000064 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise(s) reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29,2017. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 41,105 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · derivative · entry 5 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,105 Underlying: Common Stock · 41,105 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantIncentive Stock Option (right to buy) · Derivative | 8,895 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · derivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 Underlying: Common Stock · 8,895 shares Expires 2027-02-28 F2 · derivative.exercise_date: When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 30,000 | $0.00 | $30.00 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,404 F1 · balance_after: The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Tax withholdingCommon Stock | 9,631 | $10.60 | $102,088.60 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,404 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 00:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 25,000 | $0.00 | $25.00 |
DisclosureSEC source: 0001061983-17-000015 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,035 Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,326 | $12.52 | $16,600.19 |
DisclosureSEC source: 0001061983-16-000061 · edgardoc.xml · nonDerivative · entry 4 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35 Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 1,800 | $12.32 | $22,182.48 |
DisclosureSEC source: 0001061983-16-000061 · edgardoc.xml · nonDerivative · entry 3 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361 Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 200 | $12.31 | $2,461.00 |
DisclosureSEC source: 0001061983-16-000061 · edgardoc.xml · nonDerivative · entry 2 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,161 Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 21:28 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 2,307 | $12.31 | $28,399.17 |
DisclosureSEC source: 0001061983-16-000061 · edgardoc.xml · nonDerivative · entry 1 Malik Fady Ibraham · CIK 0001551778 · EVP Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,361 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.